The patent dispute between Axonics and Medtronic traces back to November 2019, when Medtronic, the long-standing leader in the SNM space, filed the lawsuit alleging that Axonics' devices infringed on its patents. Medtronic's complaint sought to protect its InterStim system, a neuromodulation technology designed to treat urinary and bowel dysfunctions, from competition. Axonics, a relatively new player in the neuromodulation market, had entered the space in 2019 with its r-SNM platform, challenging Medtronic's dominance.